Flow Cytometry Market Size, Share, and Trends 2024 to 2033

Flow Cytometry Market Size and Growth 2024 to 2033

The global flow cytometry market size was USD 5.31 billion in 2023, accounted for USD 5.70 billion in 2024, and is expected to reach around USD 11.21 billion by 2033, expanding at a CAGR of 7.80% from 2024 to 2033.

The flow cytometry market share would increase as more people contract diseases like cancer and HIV. However, issues including expensive instrument and reagent costs, a lack of awareness among prospective end users, and a shortage of technical know-how are anticipated to restrain market expansion. The preference for ow cytometry in drug research, development, and diagnostics is anticipated to provide the market potential for ow cytometry.

Flow Cytometry Market Key Takeaways

• The North America market accounted largest revenue share of around 39.78% in 2023.
• By product, the reagents & consumables segment is poised to grow at a CAGR of 8.2% from 2024 to 2033.
• By technology, the bead-based segment is growing at a CAGR of 7.7% during the forecast period 2024 to 2033.
• By application, the clinical segment is expected to reach a CAGR of 8.0% over the forecast period.
• By end user, the pharmaceutical companies segment is expected to witness growth at a CAGR of 7.9% over the forecast period.
• Asia-Pacific is expected to reach a CAGR of 8.3% over the forecast period from 2024 to 2033.

U.S. Flow Cytometry Market Size and Growth 2024 to 2033

The U.S. flow cytometry market size was estimated at USD 1.88 billion in 2023 and is predicted to be worth around USD 3.98 billion by 2033, at a CAGR of 7.8% from 2024 to 2033.

North America dominated the flow cytometry market in 2023. The growth of the market is attributed to the rising advancements in the healthcare and pharmaceutical industry, the higher prevalence of advanced flow cytometry solutions, and well-established healthcare structures in countries like the United States and Canada are driving the growth of the flow cytometry market. Rising investments in the research and development program for the development of flow cytometry devices the rising investment in research activities by the research universities and the presence of the major pharmaceutical firms contribute to the growth of the flow cytometry Market.

Asia Pacific is expected to witness significant growth in the flow cytometry market during the forecast period. The region is expected the grow in the market owing to the rising healthcare infrastructure and the rising investments by the leading healthcare companies for the development of healthcare facilities are driving the growth of the flow cytometry Market. Additionally rising availability of biotechnology and pharmaceutical firms in emerging economies like India and China. The rising cases of chronic diseases and the use of cytometry devices in several applications are driving the growth of the flow cytometry market across the region.

Flow Cytometry Market Growth Factors

The rising incidence of cancer and HIV/AIDS, the growing use of flow cytometry techniques in research, the expansion of public-private initiatives in immunology and immuno-oncology research, and the development of flow cytometry software are all major factors in the growth of the flow cytometry market.

Some of the main factors driving the growth of the flow cytometry market are the rapid advancements in technology, the rise in chronic diseases that call for validation testing, and the demand for precise and delicate methods for disease validation. In order to forecast the consequences of immunotherapy, researchers are increasingly adopting flow cytometry to subjectively and quantitatively study peripheral blood cells. High resolution, increased effectiveness, and the development of effective statistical platforms are the main factors influencing the flow cytometry industry.

Flow Cytometry Market Scope

Flow Cytometry Market Dynamics

Key Market Drivers

Studies into immunology and immuno-oncology are receiving more attention

• The major factors driving the growth of the worldwide flow cytometry market are the growing emphasis on immunology and immuno-oncology research, the rising acceptance of flow cytometry methods in research activities and clinical trials, and the expanding technical improvements.
• The market is receiving support from the growing investment and public awareness of academic research. Currently, the United Nations has put over USD 38 billion into basic and lower secondary education to fill the external funding shortfall. This will contribute to the maintenance of high standards in education while fostering strategic growth that will positively affect the progress of the country. In today's technologically advanced world, several institutions and colleges are putting unique teaching techniques into practice. This new genome-based knowledge has sparked a new era of research into single cells.
• There doesn't seem to be a stop in sight for the growth of this sector. The workhorse of the pharmaceutical sector is becoming a significant player in biotechnology. Recent research has shown that microfluidic flow cytometry devices are useful tools for handling and examining the input of single cells and micron-sized particles. The development of new products, which is expected to drive market growth over the course of the forecast period, is where the major players in the market are focusing their efforts.

The increasing number of HIV cases

• A key market driver for flow cytometry is the rise in HIV diagnoses throughout the world. This is due to the direct use of flow cytometry technology in HIV diagnosis. Light scattering is used in flow cytometry to identify cells. Depending on the kind of scattering, these cells are given specific markers known as CDs (clusters of differentiation).
• The clusters of differentiation for the HIV virus cell are known as CD4s, and flow cytometry may be used to detect HIV based on the quantity of CD4s present in a medium. The need for diagnostic methods like flow cytometry is rising along with the worldwide HIV population.

Key Market Challenges

• The availability of cheaper and better substitutes - A significant barrier to the market for flow cytometry is the existence of better and less expensive alternatives. These alternatives include radioimmunoassay and ELISA (enzyme-linked immunosorbent assay). While all three techniques flow cytometry, ELISA, and radioimmunoassay help to diagnose HIV by identifying "problem cells" among a population of cells, ELISA and radioimmunoassay are less expensive and simpler than flow cytometry.
• High cost & lack of awareness - The prevalence of chronic illnesses like cancer and HIV is predicted to rise, which will increase the use of flow cytometry in diagnostic applications. On the other side, issues including high prices for equipment and reagents, a lack of awareness among prospective end users, and a lack of technical competence are anticipated to hinder the growth of the flow cytometry market.

Key Market Opportunities

The market observed substantial growth in the bioengineering segment

• In terms of market opportunity, the bioengineering segment and its applications in a number of industries, including drug development, cell culture, and stem cell treatment, have seen significant growth. Additionally, the market is anticipated to develop as a result of the rising frequency of infectious illnesses and the rising need for quick and accurate cancer prognostic tools. In general, it is anticipated that increased demand would be driven by rising applications in the life science sector. The growth of the market is more likely to be caused by the increase in healthcare organizations that support the use of high-quality treatments and medical procedures.

Increased use of flow cytometry methods in academic and research settings

• With millions of cells per second, flow cytometry is an advanced method for detecting individual cells and other particles in suspension. Extracellular vesicle analysis, environmental studies, and the ability to employ up to 30 distinct parameters are all now possible using flow cytometry. The context of immunology is where it is most frequently used. For instance, according to a News-Medical.net story from December 2018, cancer researchers frequently utilize fluorescent-tagged monoclonal antibodies in conjunction with flow cytometry. Similarly, high-throughput image-based flow cytometry is now acknowledged and widely utilized in scientific research and academia, notably in cancer biology, following more than 10 years of intensive study.

Product Insights

The instruments segment led the flow cytometry market in 2023, accounting for the biggest revenue share of 35.08%. It is anticipated that this segment will continue to dominate the market during the forecast period. This high proportion is credited to recent technological developments and the introduction of innovative cytometers by significant players. The high cost of these devices is another factor in this segment's strong income creation.

Technology Insights

The market for flow cytometry was led by the cell-based category, which in 2023 had the highest revenue share (74.88%). Its biggest proportion is driven by rising interest in early diagnosis and expanding knowledge of the advantages of cell-based tests. Additionally, it is projected that improvements in cell-based assay technology, including innovation in tools, labels, affinity reagents, software, and algorithms, will spur usage in the upcoming years.

Infectious illness research uses tests using beads. Due to developments in molecular engineering and monoclonal antibody manufacturing and the benefits they bring, such as cost-effectiveness, a low sample need, and quick turnaround times, the market for these assays is anticipated to expand profitably throughout the projection period. These tests, also known as indirect or sandwich immunoassay formats are used to gauge the number of antibodies present in biological fluids. In these assays, conjugated antigen molecules are coated on beads to assess the presence of antibodies in the fluid.

Application Insights

With a market share of 49.08% in 2023, the research sector led the industry. It is predicted that this dominance will continue during the forecast period. The rise in R&D efforts for infectious illnesses like COVID-19 and cancer can be blamed for this high percentage. Additionally, it is anticipated that rising R&D expenditures in the pharmaceutical and biotechnology sectors would foster market expansion.

Due to the rising need for affordable illness diagnosis and the benefits of flow cytometry in disease detection, such as quicker and more precise findings, the clinical diagnostic market is predicted to develop at the quickest rate. The launch of innovative flow cytometry technologies for clinical applications and ongoing organic expansion strategies by leading companies are also projected to considerably help segment growth. For instance, in April 2019, the Chinese FDA approved the use of Cytek Biosciences' new flow cytometer, DxP Athena, which is intended for clinical diagnostic applications in labs, hospitals, and clinics.

End-Use Insights

The commercial organization sector hit notable share in the flow cytometry market.

Additionally, it is projected that there will be a significant increase in demand for flow cytometry solutions due to commercial companies' increased research efforts to discover efficient therapies for fatal diseases like cancer. On the other hand, due to the rising need for affordable detection of target diseases like cancer, the hospitals, and clinical testing labs segment is predicted to have profitable growth.

Flow Cytometry Market Companies

• Danaher Corporation
• Becton
• Dickinson and Company
• Luminex Corporation
• Agilent Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• Miltenyi Biotec
• Sysmex Corporation
• Stratedigm, Inc.
• Apogee Flow Systems Ltd.
• Sony Biotechnology, Inc.
• Thermo Fisher Scientific, Inc.

Recent Developments

• In January 2024, Sony Biotechnology launched the EC800 flow cytometry analyzer offering the greatest versatility. The latest launch EC 800 provides several affordable solutions for many applications such as viability, immunophenotyping, absolute cell counting, apoptosis, fluorescent proteins and cell cycle analysis, and particle sizing.
• In January 2024, NeoGenomics, Inc., a major provider of oncology testing services organization, and ConcertAI, LLC, a major provider of AI technology and the oncology real-world evidence data firm announced the strategic partnership for the advancements in the large-scale hematological research solution for to cover outcomes in hematological malignancies, and real-world clinical practice.
• In June 2023, BD (Becton, Dickinson, and Company), a globally recognized medical technology company announced the commercial launch of the latest automated instrument used for the making samples of clinical workflow with the use of flow cytometry, allowing the complete “Walkaway” the workflow solution designed to enhance predictability and standardization in cellular diagnostics.

Market Segmentation 

By Product

• Instruments
  • Cell Analyzers
  • Cell Sorters
• Reagents & Consumables
• Accessories
• Software
• Services

By Technology

• Cell-based
• Bead-based

By Application

• Research
  • Pharmaceutical
    • Drug Discovery
    • Stem Cell
    • In Vitro Toxicity
  • Apoptosis
  • Cell Sorting
  • Cell Cycle Analysis
  • Immunology
  • Cell Viability
• Industrial
• Clinical
  • Cancer
  • Organ Transplantation
  • Immunodeficiency
  • Hematology

By End-Use

• Commercial Organizations
• Academic Institutes
• Hospitals
• Clinical Testing Labs

By Geography

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa (MEA)